Compass Therapeutics (CMPX) Short-term Investments (2022 - 2026)

Compass Therapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $139.5 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 94.89% year-over-year to $139.5 million; the TTM figure through Mar 2026 stood at $139.5 million (up 94.89% YoY), while the FY2025 annual figure was $178.3 million, up 114.16% from the prior year.
• Short-term Investments came in at $139.5 million for Q1 2026 at Compass Therapeutics, down from $178.3 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $178.3 million in Q4 2025 to a low of $71.6 million in Q1 2025.
• A 5-year average of $125.2 million and a median of $130.4 million in 2023 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 114.16% in 2025 and fell as far as 46.01% in 2025.
• Compass Therapeutics' Short-term Investments stood at $151.7 million in 2022, then declined by 15.45% to $128.2 million in 2023, then plunged by 35.09% to $83.2 million in 2024, then surged by 114.16% to $178.3 million in 2025, then declined by 21.73% to $139.5 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $139.5 million, $178.3 million, and $173.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison